Tscan Therapeutics Inc (NASDAQ: TCRX) is -21.05% lower on its value in year-to-date trading and has touched a low of $2.43 and a high of $9.69 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TCRX stock was last observed hovering at around $2.46 in the last trading session, with the day’s loss setting it -0.06%.
Currently trading at $2.40, the stock is -16.59% and -37.06% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.24 million and changing -2.44% at the moment leaves the stock -59.59% off its SMA200. TCRX registered -58.76% loss for a year compared to 6-month loss of -65.32%. The firm has a 50-day simple moving average (SMA 50) of $3.8134 and a 200-day simple moving average (SMA200) of $5.9391.
The stock witnessed a -20.27% gain in the last 1 month and extending the period to 3 months gives it a -56.44%, and is -13.36% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.81% over the week and 6.87% over the month.
Tscan Therapeutics Inc (TCRX) has around 154 employees, a market worth around $128.09M and $9.36M in sales. Profit margin for the company is -1188.88%. Distance from 52-week low is -1.44% and -75.23% from its 52-week high. The company has generated returns on investments over the last 12 months (-35.27%).
with sales reaching $1.51M over the same period.The EPS is expected to grow by 6.43% this year, but quarterly earnings will post -82.89% year-over-year. Quarterly sales are estimated to shrink -79.06% in year-over-year returns.
Tscan Therapeutics Inc (TCRX) Top Institutional Holders
124.0 institutions hold shares in Tscan Therapeutics Inc (TCRX), with institutional investors hold 86.86% of the company’s shares. The shares outstanding are 49.08M, and float is at 43.51M with Short Float at 5.79%. Institutions hold 86.15% of the Float.
The top institutional shareholder in the company is LYNX1 CAPITAL MANAGEMENT LP with over 5.22 million shares valued at $30.56 million. The investor’s holdings represent 5.5068% of the TCRX Shares outstanding. As of 2024-06-30, the second largest holder is ECOR1 CAPITAL, LLC with 5.0 million shares valued at $29.25 million to account for 5.27 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 4.46 million shares representing 4.7034% and valued at over $26.1 million, while ADAGE CAPITAL PARTNERS GP, L.L.C. holds 4.6376 of the shares totaling 4.4 million with a market value of $25.74 million.
Tscan Therapeutics Inc (TCRX) Insider Activity
The most recent transaction is an insider purchase by Lynx1 Capital Management LP, the company’s 10% Owner. SEC filings show that Lynx1 Capital Management LP bought 100,000 shares of the company’s common stock on Dec 13 ’24 at a price of $2.90 per share for a total of $0.29 million. Following the purchase, the insider now owns 5.36 million shares.
Tscan Therapeutics Inc disclosed in a document filed with the SEC on Dec 12 ’24 that Lynx1 Capital Management LP (10% Owner) bought a total of 31,800 shares of the company’s common stock. The trade occurred on Dec 12 ’24 and was made at $3.01 per share for $95629.0. Following the transaction, the insider now directly holds 5.26 million shares of the TCRX stock.
Still, SEC filings show that on Nov 15 ’24, Lynx1 Capital Management LP (10% Owner) acquired 947 shares at an average price of $4.34 for $4114.0. The insider now directly holds 5,225,547 shares of Tscan Therapeutics Inc (TCRX).
